nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

04.01.2019 | Original Article

Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers

verfasst von: Haifa Abdulla Al-Muhtaresh, Abdel Halim Salem, Ghada Al-Kafaji

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Circulating miRNAs are increasingly suggested as clinical biomarker for diseases. We evaluated the expression of circulating cardiomyocyte-enriched miR-1 and miR-133 by real-time PCR in blood from patients with type 2 diabetes (T2D) without and with coronary artery disease (CAD) and healthy controls, investigated their association with the risk of CAD risk and their potential as biomarkers. The two miRNAs were upregulated in patients with T2D and CAD compared with controls, associated with CAD risk and remained significant after adjustment for multiple confounders. LDL-C was a positive predictor for miR-1 and miR-133, and mean blood pressure was also a positive predictor for miR-133. Both miRNAs strongly distinguished CAD from controls. miR-1 significantly distinguished CAD from T2D with higher diagnostic ability than miR-133, whereas the miR-1/miR-133 combination improved the diagnostic value. Upregulation of circulating miR-1 and miR-133 associate with the risk of CAD in T2D patients and may serve as diagnostic biomarkers.

Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047–1053.CrossRefPubMed

IDF Diabetes Atlas 5th edition. (2011). https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/20-atlas-5th-edition.html.

Alhyas, L., McKay, A., & Majeed, A. (2012). Prevalence of type 2 diabetes in the states of the co-operation council for the Arab states of the Gulf: A systematic review. PLoS One, 7, e40948.PubMedPubMedCentralCrossRef

Nathan, D. M. (1993). Long-term complications of diabetes mellitus. The New England Journal of Medicine, 328, 1676–1685.PubMedCrossRef

Laakso, M. (2010). Cardiovascular disease in type 2 diabetes from population to man to mechanisms: The Kelly West Award Lecture 2008. Diabetes Care, 33, 442–449.PubMedPubMedCentralCrossRef

Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992). The pathogenesis of coronary artery disease and the acute coronary syndromes. The New England Journal of Medicine, 326, 242–250.PubMedCrossRef

Libby, P., & Theroux, P. (2005). Pathophysiology of coronary artery disease. Circulation, 111, 3481–3488.CrossRefPubMed

Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., et al. (2007). Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ, 334(7588), 299.PubMedPubMedCentralCrossRef

Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., et al. (2008). The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet, 371, 1783–1789.PubMedCrossRef

10.

Bartel, D. P. (2004). Micrornas: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 181–197.CrossRef

11.

He, L., & Hannon, G. J. (2004). Micrornas: Small rnas with a big role in gene regulation. Nature Reviews. Genetics, 5, 522–531.PubMedCrossRef

12.

Kloosterman, W. P., & Plasterk, R. H. (2006). The diverse functions of microRNAs in animal development and disease. Developmental Cell, 11, 441–450.PubMedCrossRef

13.

Latronico, M. V., Catalucci, D., & Condorelli, G. (2007). Emerging role of microRNAs in cardiovascular biology. Circulation Research, 101, 1225–1236.PubMedCrossRef

14.

Pandey, A. K., Agarwal, P., Kaur, K., & Datta, M. (2009). MicroRNAs in diabetes: Tiny players in big disease. Cellular Physiology and Biochemistry, 23, 221–232.PubMedCrossRef

15.

Ardekani, A. M., & Naeini, M. (2010). The role of microRNAs in human diseases. Avicenna Journal of Medical Biotechnology, 2, 161–179.PubMedPubMedCentral

16.

Condorelli, G., Latronico, M. V., & Cavarretta, E. (2014). microRNAs in cardiovascular diseases current: Knowledge and the road ahead. Journal of the American College of Cardiology, 63(21), 2177–2187.PubMedCrossRef

17.

Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513–10518.PubMedPubMedCentralCrossRef

18.

Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research, 18, 997–1006.PubMedCrossRef

19.

Meder, B., Keller, A., Vogel, B., Haas, J., Sedaghat-Hameddani, F., Kayvanpour, E., et al. (2011). MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Research in Cardiology, 106, 13–23.PubMedCrossRef

20.

Al-Kafaji, G., Al-Mahroos, G., Alsayed, N. A., Hasan, Z. A., Nawaz, S., & Bakhiet, M. (2015). Peripheral blood microRNA-15a as a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Molecular Medicine Reports, 12(5), 7485–7490.PubMedCrossRef

21.

Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H. A., Skrypnyk, C., Sabry, M. A., & Ramadan, A. R. (2016). Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Experimental and Therapeutic Medicine, 12(2), 815–822.PubMedPubMedCentralCrossRef

22.

Al-Kafaji, G., Al Naieb, Z. T., & Bakhiet, M. (2016). Increased oncogenic microRNA-18a expression in peripheral blood of patients with prostate cancer: A potential role as new noninvasive biomarker. Oncology Letters, 11(2), 1201–1120.PubMedCrossRef

23.

Al-Muhtaresh, H., & Al-Kafaji, G. (2018). Evaluation of two-diabetes related microRNAs suitability as earlier blood biomarkers for detecting prediabetes and type 2 diabetes mellitus. Journal of Clinical Medical, 7(2), 12.CrossRef

24.

Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., et al. (2010). Circulating microRNAs in patients with coronary artery disease. Circulation Research, 107, 677–684.PubMedCrossRef

25.

Rao, P. K., Kumar, R. M., Farkhondeh, M., Baskerville, S., & Lodish, H. F. (2006). Myogenic factors that regulate expression of muscle-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 103, 8721–8726.PubMedPubMedCentralCrossRef

26.

Townley-Tilson, W. H., Callis, T. E., & Wang, D. (2010). MicroRNAs 1, 133, and 206: Critical factors of skeletal and cardiac muscle development, function, and disease. The International Journal of Biochemistry & Cell Biology, 42, 1252–1255.CrossRef

27.

Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016). Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). Journal of Molecular and Cellular Cardiology, 94, 107–121.PubMedCrossRef

28.

Zhao, Y., Samal, E., & Srivastava, D. (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature, 436, 214–220.PubMedCrossRef

29.

Ikeda, S., He, A., Kong, S. W., Lu, J., Bejar, R., Bodyak, N., et al. (2009). MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Molecular and Cellular Biology, 29, 2193–2204.PubMedPubMedCentralCrossRef

30.

Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., et al. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nature Genetics, 38, 228–233.PubMedCrossRef

31.

Wang, G., Zhu, J., Zhang, J., Li, Q., Li, Y., He, J., et al. (2010). Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. European Heart Journal, 31, 659–666.PubMedCrossRef

32.

Kuwabara, Y., Ono, K., Horie, T., Nishi, H., Nagoa, K., Kinoshita, M., et al. (2011). Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circulation. Cardiovascular Genetics, 4(4), 446–454.PubMedCrossRef

33.

Briasoulis, A., Tousoulis, D., Vogiatzi, G., Siasos, G., Papageorgiou, N., Oikonomou, E., et al. (2013). MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus. Current Topics in Medicinal Chemistry, 13(13), 1533–1539.PubMedCrossRef

34.

Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H., Sabry, M. A., Abdul Razzak, R., & Salem, A. H. (2017). Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. Biomarkers, 22(3–4), 268–278.PubMedCrossRef

35.

AL-Subaihi, A. (2003). Sample size determination. Influencing factors and calculation strategies for survey research. Saudi Medical Journal, 24(4), 323–330.PubMed

36.

Alberti, K. G., & Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine, 15, 539–553.PubMedCrossRef

37.

Wang, X. (2009). A PCR-based platform for microRNA expression profiling studies. RNA, 15, 716–723.PubMedPubMedCentralCrossRef

38.

Feng, Y., Niu, L.-L., Wei, W., Zhang, W.-Y., Li, X.-Y., Cao, J.-H., & Zhao, S.-H. (2013). A feedback circuit between miR-133 and the ERK1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation. Cell Death & Disease, 4, e934.CrossRef

39.

Wong, L., Lee, K., Russell, I., & Chen, C. (2007). Endogenous controls for real time quantitation of miRNA using TaqManVR MicroRNA assays. New York: Macmillan Publishers Ltd..

40.

Roggli, E., Britan, A., Gattesco, S., Lin-Marq, N., Abderrahmani, A., Meda, P., et al. (2010). Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes, 59, 978–986.PubMedPubMedCentralCrossRef

41.

Poy, M. N., Hausser, J., Trajkovski, M., Braunc, M., Collinsc, S., Rorsmanc, P., et al. (2009). miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proceedings of the National Academy of Sciences of the United States of America, 106, 5813–5818.PubMedPubMedCentralCrossRef

42.

Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 13, 613–618.PubMedCrossRef

43.

Terentyev, D., Belevych, A. E., Terentyeva, R., Martin, M. M., Malana, G. E., Kuhn, D. E., et al. (2009). miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circulation Research, 104, 514–521.PubMedPubMedCentralCrossRef

44.

Luo, X., Lin, H., Pan, Z., Xiao, J., Zhang, Y., Lu, Y., et al. (2008). Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. The Journal of Biological Chemistry, 283, 20045–20052.PubMedCrossRef

45.

Williams, A. H., Liu, N., van Rooij, E., & Olson, E. N. (2009). MicroRNA control of muscle development and disease. Current Opinion in Cell Biology, 21, 461–469.PubMedPubMedCentralCrossRef

46.

Liu, N., Bezprozvannaya, S., Williams, A. H., Qi, X., Richardson, J. A., Bassel-Duby, R., et al. (2008). microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes & Development, 22, 3242–3254.CrossRef

47.

D’Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P. G., et al. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. European Heart Journal, 31, 2765–2773.PubMedPubMedCentralCrossRef

48.

Matheus, A. S., Tannus, L. R., Cobas, R. A., Palm, A. C. C., Negrato, C. A., & Gomes, M. B. (2013). Impact of diabetes on cardiovascular disease: An update. International Journal of Hypertension, 2013, 653789.PubMedPubMedCentralCrossRef

49.

Dokken, B. B. (2008). The pathophysiology of cardiovascular disease and diabetes: Beyond blood pressure and lipids. Diabetes Spectrum: A Publication of the American Diabetes Association, 21(3), 160–165.CrossRef

50.

Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., Jr., & Fuster, V. (1999). Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American heart association and the American college of cardiology. Circulation, 100, 1481–1492.PubMedCrossRef

51.

Howard, B. V., Robbins, D. C., Sievers, M. L., et al. (2000). LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong heart study. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 830–835.PubMedCrossRef

52.

Escobar, E. (2002). Hypertension and coronary heart disease. Journal of Human Hypertension, 16(1), S61–S63.PubMedCrossRef

53.

Otsuka, T., Takada, H., Nishiyama, Y., Kodani, E., Saiki, Y., Kato, K., & Kawada, T. (2016). Dyslipidemia and the risk of developing hypertension in a working-age male population. Journal of the American Heart Association, 5, e003053.PubMedPubMedCentralCrossRef

54.

de Gonzalo-Calvo, D., van der Meer, R. W., Rijzewijk, L. J., Smit, J. W. A., Revuelta-Lopez, E., Nasarre, L., et al. (2017). Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Scientific Reports, 7(1), 47.PubMedPubMedCentralCrossRef

55.

Zhang, Z., Joyce, B. T., Kresovich, J. K., Zheng, Y., Zhong, J., Patel, R., et al. (2017). Blood pressure and expression of microRNAs in whole blood. PLoS One, 12(3), e0173550.PubMedPubMedCentralCrossRef

56.

Jepsen, A. M., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016). Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clinical Chemistry, 62(4), 593–604.PubMedCrossRef

57.

Sampson, U. K., Fazio, S., & Linton, M. F. (2012). Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges. Current Atherosclerosis Reports, 14(1), 1–10.PubMedPubMedCentralCrossRef

58.

Fruchart, J. C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., Cuevas, A., Farnier, M., et al. (2014). Residual macrovascular risk in 2013: What have we learned? Cardiovascular Diabetology, 13(1), 26.PubMedPubMedCentralCrossRef

59.

Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., & Bush, T. L. (2001). Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Archives of Internal Medicine, 161, 1413–1419.PubMedCrossRef

60.

Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003). Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. The strong heart study. Diabetes Care, 26(1), 16–23.PubMedCrossRef

61.

Kroh, E. M., Parkin, R. K., Mitchell, P. S., & Tewari, M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods, 50, 298–301.PubMedPubMedCentralCrossRef

62.

Li, Y., & Kowdley, K. V. (2012). Method for microRNA isolation from clinical serum samples. Analytical Biochemistry, 431(1), 69–75.PubMedPubMedCentralCrossRef

Titel: Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers
verfasst von: Haifa Abdulla Al-Muhtaresh
Abdel Halim Salem
Ghada Al-Kafaji
Publikationsdatum: 04.01.2019
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2019
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-018-9857-2

Neu im Fachgebiet Kardiologie

23.04.2024 | Ablationstherapie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers

Abstract

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of Concept

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

Ex Vivo Pilot Study of Cardiac Magnetic Resonance Velocity Mapping for Quantification of Aortic Regurgitation in a Porcine Model in the Presence of a Transcatheter Heart Valve

Intra-aortic Balloon Counterpulsation for High-Risk Percutaneous Coronary Intervention: Defining Coronary Responders

Loss of Regulatory Immune Function in Coronary Artery Disease Patients from the Indian Population

A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie